Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7,263 treatment courses
Autore:
Gaertner, I; Altendorf, K; Batra, A; Gaertner, HJ;
Indirizzi:
Univ Tubingen, Clin Psychiat & Psychotherapy, D-72076 Tubingen, Germany Univ Tubingen Tubingen Germany D-72076 herapy, D-72076 Tubingen, Germany
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 21, anno: 2001,
pagine: 215 - 222
SICI:
0271-0749(200104)21:2<215:ROLEEW>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLOZAPINE; HEPATOTOXICITY; DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Gaertner, I Univ Tubingen, Clin Psychiat & Psychotherapy, Osianderstr 24, D-72076 Tubingen, Germany Univ Tubingen Osianderstr 24 Tubingen Germany D-72076 Germany
Citazione:
I. Gaertner et al., "Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7,263 treatment courses", J CL PSYCH, 21(2), 2001, pp. 215-222

Abstract

Data on liver enzyme elevations were collected in a retrospective study of7,263 treatment courses with haloperidol, clozapine, perphenazine, and perazine. Charts of 233 patients hospitalized between 1980 and 1992 at Tubingen University Psychiatric Clinic were selected because clinically relevant increases of Liver enzymes had been detected during monotherapy with one of the four examined neuroleptics. At least one hepatic enzyme (mostly alanineaminotransferase [ALAT]) exceeded the established reference range of 3-fold elevations of ALAT, aspartate aminotransferase, gamma -glutamyl transpeptidase, and glutamate dehydrogenase and 2-fold elevations of alkaline phosphatase (AP) during monotherapy with clozapine in 15%, perazine in 7.6%, perphenazine in 4%, and haloperidol in 2.4% of the cases. If all Liver enzyme abnormalities with any elevation greater than the conventional upper limits are considered, incidences were as follows: clozapine, 78%; perphenazine, 62%; perazine, 59%; and haloperidol, 50%. Testing for overall differences within the four neuroleptics resulted in significantly different incidences of Liver enzyme elevations (chi (2) test, p < 0.0001). Threefold increases of AP (>540 U/L) were seen in three patients receiving haloperidol (0.3%) only. Twofold increases of AP (>360 U/L) were distributed as follows: clozapine, 1%; haloperidol, 0.8%; perazine, 0.3%; and perphenazine, 0.1%. Only in the group with 1-fold elevations of AP (>180 U/L) were the differences within the drug regimens significant (clozapine, 40.3%; haloperidol, 33.2%; perphenazine, 23.4%; and perazine, 23.1%; chi (2) test, p < 0.0001). In the period under study, no instance of icterus occurred.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/20 alle ore 20:36:40